107910-75-8
107910-75-8 結(jié)構(gòu)式
基本信息
注射更昔洛韋
更昔洛韋雜質(zhì)7
更昔洛韋鈉原料藥
更昔洛韋鈉(二水)
更昔洛韋鈉[干冰運(yùn)輸,需加收額外費(fèi)用]
9-(1,3-二羥基-2-丙氧甲基)-鳥嘌呤鈉
Rs 21592 sodium
GANCICLOVIR SODIUM
Sodium Ganciclovir
Cytovene IV sodium
Gancyclovir sodium
Ganciclovir Impurity 7
Ganciclovir Sodium Salt
Ganciclovir sodium, >=98%
Ganciclovir monosodium salt
物理化學(xué)性質(zhì)
常見問題列表
2．預(yù)防可能發(fā)生于接受器官移植者的巨細(xì)胞病毒感染。
2. 預(yù)防可能發(fā)生于接受器官移植者的巨細(xì)胞病毒感染：腎功能正常者：靜脈滴注，一次5mg/kg，每12小時(shí)一次，連用7天～14天后，改為一次5mg/kg，一日1次，一周用7天，或一次6 mg/kg，一日1次，每周用5天，或遵醫(yī)囑。每次靜脈滴注時(shí)間不少于1小時(shí)。
|
CMV
|
HSV-1
|
HSV-2
|
FHV-1 5.2 μM (IC 50 ) |
Ganciclovir sodium is an acyclic deoxyguanosine analog structurally similar to acyclovir but with superior activity against CMV. The median ganciclovir concentration required to inhibit viral replication by 50 percent is 2.15 mumol versus 72 mumol for acyclovir.The primary mechanism of ganciclovir action against CMV is inhibition of the replication of viral DNA by ganciclovir-5'-triphosphate (ganciclovir-TP). This inhibition includes a selective and potent inhibition of the viral DNA polymerase. Ganciclovir sodium is metabolized to the triphosphate form by primarily three cellular enzymes: a deoxyguanosine kinase induced by CMV-infected cells; guanylate kinase; and phosphoglycerate kinase.
Ganciclovir sodium (1-80 mg/kg; i.h.; daily for 5 days) delays MCMV-induced wasting syndrome and mortality.
| Animal Model: | Severe combined immunodeficiency (SCID) mice (MCMV infection) |
| Dosage: | 1-80 mg/kg |
| Administration: | I.h.; daily for 5 days |
| Result: | Dose dependently delayed MCMV-induced wasting syndrome and mortality. |